A Randomised, Single-blind, Placebo-controlled Single-centre Phase I Study in Healthy Male Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of AZD2820 After Single Ascending Doses.
Latest Information Update: 25 Jan 2016
At a glance
- Drugs AZD 2820 (Primary)
- Indications Obesity
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 18 Nov 2011 Actual end date Nov 2011 added as reported by ClinicalTrials.gov.
- 18 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Oct 2011 Planned End Date changed from 1 Sep 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.